Cerebrospinal Fluid Repository (CSF)
|Amyotrophic Lateral Sclerosis Cerebrospinal Fluid Neurodegenerative Disease Motor Neuron Disease|
|Study Design:||Observational Model: Case-Control
Time Perspective: Cross-Sectional
|Official Title:||Cerebrospinal Fluid Repository|
|Study Start Date:||October 2006|
|Study Completion Date:||October 2008|
|Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
Subjects having either definite or probable ALS by El Escorial Criteria.
Subjects not having either definite or probable ALS by El Escorial Criteria.
The only specific procedures unique to this protocol is the collection of an additional 3ml or less of cerebrospinal fluid from a lumbar puncture already being performed and the collection of clinical information from the patients medical records. Lumbar puncture may be either a research procedure or a standard of care procedure, depending upon the reason for initiating the puncture. We will aliquot the additional fluid into a separate storage container and it will be maintained in the laboratory of Dr. Heiman-Patterson at -70 degrees. Clinical information including age, medical and neurological history, laboratory data, and pathologic information where indicated will be abstracted from the patient chart. All specimens and corresponding clinical information will be labeled with an identification number and sorted by diagnosis. There will be no patient identifying information kept with the specimens. The CSF sample may be used for studies performed by researchers at Drexel University College of Medicine or shared with collaborators. The CSF sample provided will only be used for projects that have approval by the IRB, but subjects will not be notified each time it is used for a study. If CSF sample is still available, consent can be withdrawn at any time by writing a letter to Dr. Heiman-Patterson requesting the withdrawal of the sample.
Researchers will request control and disease specific samples to use in various research studies. There are no DNA studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00714636
|United States, Pennsylvania|
|MDA/ALS Center of Hope|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Terry Heiman-Patterson, MD||MDA/ALS Center of Hope|